Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 54, Issue 47, Pages 14049-14052Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201507800
Keywords
cancer therapy; lysosomes; photodynamic therapy; ruthenium; singlet oxygen
Categories
Funding
- 973 Program [2015CB856301]
- National Science Foundation of China [21172273, 21171177, 21471164, J1103305]
- Program for Changjiang Scholars and Innovative Research Team at the University of China [IRT1298]
- Swiss National Science Foundation (SNSF) [PP00P2_133568, PP00P2_157545]
- University of Zurich
- China Scholarships Council [201506380026]
Ask authors/readers for more resources
Photodynamic therapy (PDT) is a noninvasive medical technique that has received increasing attention over the last years and been applied for the treatment of certain types of cancer. However, the currently clinically used PDT agents have several limitations, such as low water solubility, poor photostability, and limited selectivity towards cancer cells, aside from having very low two-photon cross-sections around 800 nm, which limits their potential use in TP-PDT. To tackle these drawbacks, three highly positively charged ruthenium(II) polypyridyl complexes were synthesized. These complexes selectively localize in the lysosomes, an ideal localization for PDT purposes. One of these complexes showed an impressive phototoxicity index upon irradiation at 800 nm in 3D HeLa multicellular tumor spheroids and thus holds great promise for applications in two-photon photodynamic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available